Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Dyslipidaemia management

Lifestyle changes, such as smoking cessation, losing weight and increasing physical activity, can reduce cardiovascular risk for patients with dyslipidaema. Statins are used first line for most patients. Beyond statins, the National Institute for Health and Care Excellence suggests that ezetimibe in combination with statin therapy can be considered, but should be reserved until statin therapy has been fully optimised.

Exercising regularly can help patients lose weight and lower cholesterol levels (Diego.cervo/Dreamstime)Summary

Lifestyle changes, such as smoking cessation, losing weight and increasing physical activity, can reduce cardiovascular risk for patients with dyslipidaema. Statins are used first line for most patients. Beyond statins, the National Institute for Health and Care Excellence suggests that ezetimibe in combination with statin therapy can be considered, but should be reserved until statin therapy has been fully optimised.

For patients unable to tolerate statins, fibrates, bile acid sequestrants, nicotinic acid derivatives and ezetimibe are all valid options. For patients with hypertriglyceridaemia, fibrates and omega-3 fatty acid compounds are useful, with or without statin therapy. 

Helen Williams is consultant pharmacist for cardiovascular disease, medicines management team, Southwark Clinical Commissioning Group.

E: helen.williams11@nhs.net

Citation: Clinical Pharmacist DOI: 10.1211/CP.2013.11125100

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.